Ignite Creation Date:
2025-12-24 @ 7:06 PM
Ignite Modification Date:
2026-02-21 @ 10:12 PM
Study NCT ID:
NCT04535557
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2022-09-30
First Post:
2020-08-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations
Sponsor:
Millennium Pharmaceuticals, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
Mobocertinib EAP
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None